Your fact-checks will appear here
American think tank (2001-)
The 2025–2026 Northern Hemisphere flu vaccines are trivalent and chosen to target one H1N1 A strain, one H3N2 A strain, and one B/Victoria-lineage strain; U.S. regulators (FDA/CDC) recommended these c...
Common short-term side effects after COVID-19 vaccination — pain at the injection site, fatigue, headache, muscle aches, chills and fever — typically appear within a day and resolve within a few days ...
The FDA and WHO recommended trivalent vaccine strains for 2025–26 (H1N1, H3N2, B/Victoria) and changed the H3N2 component for egg‑ and cell‑based vaccines to improve antigenic match . However, multipl...
Peer-reviewed, long-term (3–5+ year) studies specifically designed to follow people from COVID-19 vaccination through three to five or more years are limited in the public record; most large safety ef...
A simple, single percentage that answers “” is not available in the public datasets provided; global death dashboards track COVID deaths but do not report a straightforward fraction of vaccine recipie...
Original mRNA COVID-19 vaccines (Pfizer-BioNTech, Moderna) introduced in late 2020 used lipid nanoparticle-formulated mRNA and a short list of excipients; later updates from 2022–2024 shifted only the...
Early real-world data from the UK indicate the 2025–26 vaccine is reducing hospital attendance for pediatric H3N2 cases by about 70–75% and by roughly 30–40% in adults, even as a drifted H3N2 “subclad...
Unapproved “detox” regimens promoted for vaccine side effects can pose health risks, especially if they delay medical care or involve untested ingredients; mainstream public-health sources emphasize t...
Older adults (65+) are urged to get updated COVID-19 vaccines because they remain most at risk for severe outcomes; vaccine effectiveness against hospitalization in immunocompetent adults ≥65 was abou...
Major public-health institutions and mainstream research outlets have repeatedly rejected the idea that vaccines are a covert tool for “overpopulation” or depopulation. Reviews and reporting from the ...
Early real-world data from the UK show the 2025–26 vaccine is reducing hospital attendance for children aged 2–17 by roughly 70–75% and protecting adults at substantially lower levels—about 30–40% aga...
Major, peer-reviewed and public-health sources in the provided set report that COVID-19 vaccines reduce severe illness, hospitalization and death and that researchers continue to study longer-term out...
Most public reports say the 2025–26 Northern Hemisphere vaccine’s H3N2 component was chosen months before a genetically distinct H3N2 “subclade K” (aka K strain) began spreading, and that subclade K c...
Available reporting says serious adverse events after COVID-19 vaccination are rare and that myocarditis is one of the better-documented, very uncommon risks; public-health authorities emphasize vacci...
Available reporting shows COVID-19 vaccination coverage in the U.S. rose sharply during 2020–2021 and has declined year‑by‑year since, with 2024–2025 and 2025 seasons cited as having substantially low...
Available reporting shows mixed evidence about how well recent vaccines protect against currently circulating influenza viruses: Southern Hemisphere 2025 interim data suggest roughly 50% reduction in ...
A small but visible set of papers and commentaries have argued that COVID-19 vaccine effectiveness was overstated or that safety signals were under-reported; prominent examples include a MedRxiv prepr...
Peer‑reviewed papers and meta‑analyses have examined excess mortality and deaths temporally associated with COVID‑19 vaccines; results are mixed and contested. Some recent peer‑reviewed articles repor...
For the 2025–26 U.S. season, most manufacturers are supplying single‑dose, thimerosal‑free prefilled syringes — specifically GSK’s Fluarix and Flulaval, Seqirus’s Afluria and Fluad, and CSL Seqirus’s ...
Available sources provided in the search set do not supply a single, clear figure for the overall UK flu vaccination uptake rate for 2024–2025; reporting instead focuses on vaccine effectiveness, hosp...